New sleep apnea pill cuts breathing interruptions by 44% in phase 3 trial

The drug AD109, taken once nightly, cut breathing interruptions by about 44% in a major phase 3 clinical trial, while also improving blood oxygen levels and disease severity. It works by strengthening muscles that keep the airway open during sleep, potentially offering an alternative to CPAP for patients who cannot tolerate the device.